Mounjaro and Gallbladder Disease: Alternatives Without This Side Effect

What does the Mounjaro label say about gallbladder disease?

Mounjaro is approved for type 2 diabetes in adults and children 10 years and older, and to reduce major cardiovascular events in adults with type 2 diabetes at high risk; it is not labeled for weight loss [1]. The label lists acute gallbladder disease under warnings and precautions. In adult placebo-controlled trials, acute gallbladder disease (cholelithiasis, biliary colic, and cholecystectomy) was reported by 0.6% of Mounjaro-treated patients and 0% of placebo-treated patients [1]. The label says if cholelithiasis is suspected, gallbladder studies and clinical follow-up are indicated [1].

Why might tirzepatide affect the gallbladder?

Rapid weight loss is a recognized risk factor for cholesterol gallstones. A review of obesity and gallstone disease notes that very-low-calorie diets and bariatric surgery, both of which produce rapid weight loss, increase cholelithiasis risk [9]. GLP-1 receptor activation may also change gallbladder emptying. In a randomized crossover study of healthy fasting volunteers, a single 10 microgram dose of exenatide lowered the maximum gallbladder ejection fraction during cholecystokinin infusion to 28.79% versus 46.13% with placebo [10]. That study tested exenatide, not tirzepatide. A review of GLP-1-based therapies notes that their effects on the gallbladder may also be beneficial, but that they potentially increase the risk of biliary disease [11].

A 2023 meta-analysis of nine randomized trials (9,871 participants) found a higher rate of the composite of gallbladder or biliary disease with tirzepatide than with placebo or basal insulin (RR 1.97, 95% CI 1.14 to 3.42) [5]. The same analysis did not find a significant association with cholelithiasis, cholecystitis or biliary disease individually [5].

Are there alternatives without gallbladder risk?

Metformin, SGLT2 inhibitors, DPP-4 inhibitors and pioglitazone are non-GLP-1 options for type 2 diabetes [12][2][3][4]. The cited results for dapagliflozin, pioglitazone and sitagliptin are cardiovascular outcome trials, and the metformin source is a historical overview; they do not give gallbladder rates for these drugs or compare their gallbladder risk with Mounjaro [12][2][3][4].

GLP-1 receptor agonists as a class have also been associated with gallbladder disorders: a meta-analysis of 21 randomized trials (99,599 patients) found a 26% increase compared with controls [6].

Can ursodiol or diet reduce gallstones during weight loss?

Ursodiol has randomized evidence for preventing gallstones during weight loss. A meta-analysis of 13 randomized trials (1,836 participants) found ursodeoxycholic acid reduced ultrasound-verified gallstones compared with control (RR 0.33, 95% CI 0.18 to 0.60; number needed to treat 9) [7]. In a 1995 multicenter trial after gastric bypass, gallstones formed by 6 months in 2% of patients on ursodiol 600 mg daily versus 32% on placebo [8]. Those trials tested weight-loss diets and gastric bypass, not tirzepatide.

The same meta-analysis found higher-fat weight-loss diets reduced gallstones compared with low-fat diets (RR 0.09, 95% CI 0.01 to 0.61) [7]. That finding is about weight-loss diets generally, not a tested Mounjaro regimen.